DFA NY Municipal Bond Portfolio Institutional Class (DNYMX) investicinio fondo vieneto kaina ir naujienos

PagrindinisDNYMX • Investiciniai fondai

DFA NY Municipal Bond Portfolio Institutional Class

10,19 $

02-12 · USD · MUTF · Atsisakymas

DFA Emerging Markets Value Portfolio Institutional Class

41,28 $

DFEVX0,53 %

DFA Large Cap International Portfolio Institutional Class

37,59 $

DFALX1,08 %

DFA Short-Term Government Portfolio Institutional Class

9,98 $

DFFGX0,00 %

DFA U.S. Sustainability Targeted Value Portfolio Institutional Class

23,45 $

DAABX1,39 %

DFA U.S. Small Cap Value Portfolio Institutional Class

57,63 $

DFSVX1,69 %

DFA LTIP Portfolio Institutional Class

5,31 $

DRXIX1,72 %

DFA California Short Term Municipal Bond Portfolio Institutional Class

10,26 $

DFCMX0,00 %

Dimensional 2025 Target Date Retirement Income Fund Institutional Class

11,49 $

DRIUX0,17 %

DFA World ex U.S. Core Equity Portfolio Institutional Class Shares

18,43 $

DFWIX1,02 %

DFA International Small Cap Value Portfolio Institutional Class

34,65 $

DISVX1,03 %

Investicinis fondas

Ankstesnė uždarymo kaina

10,19 $

Grąža nuo einamųjų metų pradžios

0,43 %

Išlaidų rodiklis

0,25 %

Kategorija

US Municipal Fixed Income

„Morningstar“ įvertis

Grynasis turtas

170,94 mln. USD

Pelningumas

2,73 %

Pirminės apkrovos mokestis

Pradžios data

2015-06-16

Rinkos naujienos

Portalas investuotojams

prieš 6 minutes

Veiklos rezultatų skelbimo sezonas kol kas pozityvus, bet tarp investuotojų euforijos nėra

KARK

prieš 2 valandas

World shares mixed after sharp Wall Street losses on AI-related worries

Business Wire

prieš 1 dieną

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACCESS Newswire

prieš 1 dieną

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

VNET taps homegrown finance leader Peter Zhang to oversee financial operations

Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim

TRDA

2,44 %